Lung carcinoma with ALK rearrangement - Revision history

Michael: /* General */

2019-03-17T23:57:05Z

General

← Older revision		Revision as of 23:57, 17 March 2019
Line 7:		Line 7:
	**Typically seen in nonsmokers and younger age patients.		**Typically seen in nonsmokers and younger age patients.
	**Can be treated with ''[[crizotinib]]''.<ref name=pmid21475126>{{Cite journal \| last1 = Crystal \| first1 = AS. \| last2 = Shaw \| first2 = AT. \| title = New targets in advanced NSCLC: EML4-ALK. \| journal = Clin Adv Hematol Oncol \| volume = 9 \| issue = 3 \| pages = 207-14 \| month = Mar \| year = 2011 \| doi = \| PMID = 21475126 }}</ref>		**Can be treated with ''[[crizotinib]]''.<ref name=pmid21475126>{{Cite journal \| last1 = Crystal \| first1 = AS. \| last2 = Shaw \| first2 = AT. \| title = New targets in advanced NSCLC: EML4-ALK. \| journal = Clin Adv Hematol Oncol \| volume = 9 \| issue = 3 \| pages = 207-14 \| month = Mar \| year = 2011 \| doi = \| PMID = 21475126 }}</ref>
	***Resistance to ALK inhibitors may occur due mutations in kinase domain.		***Resistance to [[ALK inhibitors]] may occur due mutations in kinase domain.
	***Ceritinib is indicated for tumor with acquired resistance to crizotinib.<ref>{{Cite journal \| last1 = Shaw \| first1 = AT. \| last2 = Kim \| first2 = DW. \| last3 = Mehra \| first3 = R. \| last4 = Tan \| first4 = DS. \| last5 = Felip \| first5 = E. \| last6 = Chow \| first6 = LQ. \| last7 = Camidge \| first7 = DR. \| last8 = Vansteenkiste \| first8 = J. \| last9 = Sharma \| first9 = S. \| title = Ceritinib in ALK-rearranged non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 370 \| issue = 13 \| pages = 1189-97 \| month = Mar \| year = 2014 \| doi = 10.1056/NEJMoa1311107 \| PMID = 24670165 }}</ref>		***Ceritinib is indicated for tumor with acquired resistance to crizotinib.<ref>{{Cite journal \| last1 = Shaw \| first1 = AT. \| last2 = Kim \| first2 = DW. \| last3 = Mehra \| first3 = R. \| last4 = Tan \| first4 = DS. \| last5 = Felip \| first5 = E. \| last6 = Chow \| first6 = LQ. \| last7 = Camidge \| first7 = DR. \| last8 = Vansteenkiste \| first8 = J. \| last9 = Sharma \| first9 = S. \| title = Ceritinib in ALK-rearranged non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 370 \| issue = 13 \| pages = 1189-97 \| month = Mar \| year = 2014 \| doi = 10.1056/NEJMoa1311107 \| PMID = 24670165 }}</ref>
	*Testing in [[FFPE]] tissue requires ~100 cells.<ref name=pmid25806315>{{Cite journal \| last1 = Popper \| first1 = HH. \| last2 = Tímár \| first2 = J. \| last3 = Ryska \| first3 = A. \| last4 = Olszewski \| first4 = W. \| title = Minimal requirements for the molecular testing of lung cancer. \| journal = Transl Lung Cancer Res \| volume = 3 \| issue = 5 \| pages = 301-4 \| month = Oct \| year = 2014 \| doi = 10.3978/j.issn.2218-6751.2014.10.02 \| PMID = 25806315 }}</ref>		*Testing in [[FFPE]] tissue requires ~100 cells.<ref name=pmid25806315>{{Cite journal \| last1 = Popper \| first1 = HH. \| last2 = Tímár \| first2 = J. \| last3 = Ryska \| first3 = A. \| last4 = Olszewski \| first4 = W. \| title = Minimal requirements for the molecular testing of lung cancer. \| journal = Transl Lung Cancer Res \| volume = 3 \| issue = 5 \| pages = 301-4 \| month = Oct \| year = 2014 \| doi = 10.3978/j.issn.2218-6751.2014.10.02 \| PMID = 25806315 }}</ref>

Michael: /* See also */

2019-03-08T18:31:57Z

Michael: /* General */

2018-09-07T16:43:52Z

General

← Older revision		Revision as of 16:43, 7 September 2018
Line 3:		Line 3:

	==General==		==General==
	ALK (~~Anaplastic~~ lymphoma receptor tyrosine kinase)		ALK (anaplastic lymphoma (receptor tyrosine) kinase):
	*Approximately 1-5% non-small cell lung carcinoma.<ref name=pmid21753699>{{Cite journal \| last1 = Yoshida \| first1 = A. \| last2 = Tsuta \| first2 = K. \| last3 = Nakamura \| first3 = H. \| last4 = Kohno \| first4 = T. \| last5 = Takahashi \| first5 = F. \| last6 = Asamura \| first6 = H. \| last7 = Sekine \| first7 = I. \| last8 = Fukayama \| first8 = M. \| last9 = Shibata \| first9 = T. \| title = Comprehensive histologic analysis of ALK-rearranged lung carcinomas. \| journal = Am J Surg Pathol \| volume = 35 \| issue = 8 \| pages = 1226-34 \| month = Aug \| year = 2011 \| doi = 10.1097/PAS.0b013e3182233e06 \| PMID = 21753699 }}</ref>		*Approximately 1-5% non-small cell lung carcinoma.<ref name=pmid21753699>{{Cite journal \| last1 = Yoshida \| first1 = A. \| last2 = Tsuta \| first2 = K. \| last3 = Nakamura \| first3 = H. \| last4 = Kohno \| first4 = T. \| last5 = Takahashi \| first5 = F. \| last6 = Asamura \| first6 = H. \| last7 = Sekine \| first7 = I. \| last8 = Fukayama \| first8 = M. \| last9 = Shibata \| first9 = T. \| title = Comprehensive histologic analysis of ALK-rearranged lung carcinomas. \| journal = Am J Surg Pathol \| volume = 35 \| issue = 8 \| pages = 1226-34 \| month = Aug \| year = 2011 \| doi = 10.1097/PAS.0b013e3182233e06 \| PMID = 21753699 }}</ref>
	**Typically seen in nonsmokers and younger age patients.		**Typically seen in nonsmokers and younger age patients.

Michael: /* Images */

2018-09-07T03:21:06Z

Images

← Older revision		Revision as of 03:21, 7 September 2018
Line 24:		Line 24:
	===Images===		===Images===
	<gallery>		<gallery>
	Image: ALK positive lung adenocarcinoma -- very low mag.jpg \| ALK +ve lung adenoca - very low mag.		Image: ALK positive lung adenocarcinoma -- very low mag.jpg \| ALK +ve lung adenoca - very low mag. (WC)
	Image: ALK positive lung adenocarcinoma -- low mag.jpg \| ALK +ve lung adenoca - low mag.		Image: ALK positive lung adenocarcinoma -- low mag.jpg \| ALK +ve lung adenoca - low mag. (WC)
	Image: ALK positive lung adenocarcinoma -- intermed mag.jpg \| ALK +ve lung adenoca - intermed. mag.		Image: ALK positive lung adenocarcinoma -- intermed mag.jpg \| ALK +ve lung adenoca - intermed. mag. (WC)
	Image: ALK positive lung adenocarcinoma -- high mag.jpg \| ALK +ve lung adenoca - high mag.		Image: ALK positive lung adenocarcinoma -- high mag.jpg \| ALK +ve lung adenoca - high mag. (WC)
	Image: ALK positive lung adenocarcinoma -- very high mag.jpg \| ALK +ve lung adenoca - very high mag.		Image: ALK positive lung adenocarcinoma -- very high mag.jpg \| ALK +ve lung adenoca - very high mag. (WC)
	</gallery>		</gallery>
	====www====		====www====

Michael: /* IHC */ +images

2018-09-07T03:20:48Z

IHC: +images

← Older revision		Revision as of 03:20, 7 September 2018
Line 39:		Line 39:
	*TTF-1 +ve.		*TTF-1 +ve.
	*ALK +ve.{{fact}}		*ALK +ve.{{fact}}

			===Images===
			<gallery>
			Image: ALK positive lung adenocarcinoma - ALK IHC -- very low mag.jpg \| ALK +ve lung adenoca - very low mag. (WC)
			Image: ALK positive lung adenocarcinoma - ALK IHC -- low mag.jpg \| ALK +ve lung adenoca - low mag. (WC)
			Image: ALK positive lung adenocarcinoma - ALK IHC -- intermed mag.jpg \| ALK +ve lung adenoca - intermed. mag. (WC)
			Image: ALK positive lung adenocarcinoma - ALK IHC -- high mag.jpg \| ALK +ve lung adenoca - high mag. (WC)
			Image: ALK positive lung adenocarcinoma - ALK IHC -- very high mag.jpg \| ALK +ve lung adenoca - very high mag. (WC)
			</gallery>

	==Molecular==		==Molecular==

Michael: /* Microscopic */ more images

2018-09-07T01:30:01Z

Microscopic: more images

← Older revision		Revision as of 01:30, 7 September 2018
Line 23:		Line 23:

	===Images===		===Images===
			<gallery>
			Image: ALK positive lung adenocarcinoma -- very low mag.jpg \| ALK +ve lung adenoca - very low mag.
			Image: ALK positive lung adenocarcinoma -- low mag.jpg \| ALK +ve lung adenoca - low mag.
			Image: ALK positive lung adenocarcinoma -- intermed mag.jpg \| ALK +ve lung adenoca - intermed. mag.
			Image: ALK positive lung adenocarcinoma -- high mag.jpg \| ALK +ve lung adenoca - high mag.
			Image: ALK positive lung adenocarcinoma -- very high mag.jpg \| ALK +ve lung adenoca - very high mag.
			</gallery>
			====www====
	*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400179/figure/f1-cln_67p845/ Lung carcinoma with ALK rearrangement (nih.gov)].<ref name=pmid22892933>{{Cite journal \| last1 = Lopes \| first1 = LF. \| last2 = Bacchi \| first2 = CE. \| title = Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population. \| journal = Clinics (Sao Paulo) \| volume = 67 \| issue = 7 \| pages = 845-7 \| month = Jul \| year = 2012 \| doi = \| PMID = 22892933 }}</ref>		*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400179/figure/f1-cln_67p845/ Lung carcinoma with ALK rearrangement (nih.gov)].<ref name=pmid22892933>{{Cite journal \| last1 = Lopes \| first1 = LF. \| last2 = Bacchi \| first2 = CE. \| title = Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population. \| journal = Clinics (Sao Paulo) \| volume = 67 \| issue = 7 \| pages = 845-7 \| month = Jul \| year = 2012 \| doi = \| PMID = 22892933 }}</ref>
	*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731315/figure/pone-0069794-g002/ Lung carcinoma with ALK rearrangment (nih.gov)]<ref>{{Cite journal \| last1 = Takamochi \| first1 = K. \| last2 = Takeuchi \| first2 = K. \| last3 = Hayashi \| first3 = T. \| last4 = Oh \| first4 = S. \| last5 = Suzuki \| first5 = K. \| title = A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. \| journal = PLoS One \| volume = 8 \| issue = 8 \| pages = e69794 \| month = \| year = 2013 \| doi = 10.1371/journal.pone.0069794 \| PMID = 23936355 }}</ref> - [http://www.plosone.org/article/info:doi/10.1371/journal.pone.0069794.g002/largerimage high resolution (plosone.org)].		*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731315/figure/pone-0069794-g002/ Lung carcinoma with ALK rearrangment (nih.gov)]<ref>{{Cite journal \| last1 = Takamochi \| first1 = K. \| last2 = Takeuchi \| first2 = K. \| last3 = Hayashi \| first3 = T. \| last4 = Oh \| first4 = S. \| last5 = Suzuki \| first5 = K. \| title = A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. \| journal = PLoS One \| volume = 8 \| issue = 8 \| pages = e69794 \| month = \| year = 2013 \| doi = 10.1371/journal.pone.0069794 \| PMID = 23936355 }}</ref> - [http://www.plosone.org/article/info:doi/10.1371/journal.pone.0069794.g002/largerimage high resolution (plosone.org)].

Michael: +images

2018-09-07T01:29:05Z

+images

← Older revision		Revision as of 01:29, 7 September 2018
Line 1:		Line 1:
			[[Image:ALK positive lung adenocarcinoma -- low mag.jpg\|thumb\|right\|[[Micrograph]] showing ALK positive lung adenocarcinoma. [[H&E stain]].]]
	'''Lung carcinoma with ALK rearrangement''' is subset of [[lung adenocarcinoma]].		'''Lung carcinoma with ALK rearrangement''' is subset of [[lung adenocarcinoma]].

Michael: /* General */

2017-10-19T13:23:58Z

General

← Older revision		Revision as of 13:23, 19 October 2017
Line 8:		Line 8:
	***Resistance to ALK inhibitors may occur due mutations in kinase domain.		***Resistance to ALK inhibitors may occur due mutations in kinase domain.
	***Ceritinib is indicated for tumor with acquired resistance to crizotinib.<ref>{{Cite journal \| last1 = Shaw \| first1 = AT. \| last2 = Kim \| first2 = DW. \| last3 = Mehra \| first3 = R. \| last4 = Tan \| first4 = DS. \| last5 = Felip \| first5 = E. \| last6 = Chow \| first6 = LQ. \| last7 = Camidge \| first7 = DR. \| last8 = Vansteenkiste \| first8 = J. \| last9 = Sharma \| first9 = S. \| title = Ceritinib in ALK-rearranged non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 370 \| issue = 13 \| pages = 1189-97 \| month = Mar \| year = 2014 \| doi = 10.1056/NEJMoa1311107 \| PMID = 24670165 }}</ref>		***Ceritinib is indicated for tumor with acquired resistance to crizotinib.<ref>{{Cite journal \| last1 = Shaw \| first1 = AT. \| last2 = Kim \| first2 = DW. \| last3 = Mehra \| first3 = R. \| last4 = Tan \| first4 = DS. \| last5 = Felip \| first5 = E. \| last6 = Chow \| first6 = LQ. \| last7 = Camidge \| first7 = DR. \| last8 = Vansteenkiste \| first8 = J. \| last9 = Sharma \| first9 = S. \| title = Ceritinib in ALK-rearranged non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 370 \| issue = 13 \| pages = 1189-97 \| month = Mar \| year = 2014 \| doi = 10.1056/NEJMoa1311107 \| PMID = 24670165 }}</ref>
	*Testing in [[FFPE]] requires ~100 cells.<ref name=pmid25806315>{{Cite journal \| last1 = Popper \| first1 = HH. \| last2 = Tímár \| first2 = J. \| last3 = Ryska \| first3 = A. \| last4 = Olszewski \| first4 = W. \| title = Minimal requirements for the molecular testing of lung cancer. \| journal = Transl Lung Cancer Res \| volume = 3 \| issue = 5 \| pages = 301-4 \| month = Oct \| year = 2014 \| doi = 10.3978/j.issn.2218-6751.2014.10.02 \| PMID = 25806315 }}</ref>		*Testing in [[FFPE]] tissue requires ~100 cells.<ref name=pmid25806315>{{Cite journal \| last1 = Popper \| first1 = HH. \| last2 = Tímár \| first2 = J. \| last3 = Ryska \| first3 = A. \| last4 = Olszewski \| first4 = W. \| title = Minimal requirements for the molecular testing of lung cancer. \| journal = Transl Lung Cancer Res \| volume = 3 \| issue = 5 \| pages = 301-4 \| month = Oct \| year = 2014 \| doi = 10.3978/j.issn.2218-6751.2014.10.02 \| PMID = 25806315 }}</ref>

	==Microscopic==		==Microscopic==

Michael at 13:21, 19 October 2017

2017-10-19T13:21:27Z

← Older revision		Revision as of 13:21, 19 October 2017
Line 8:		Line 8:
	***Resistance to ALK inhibitors may occur due mutations in kinase domain.		***Resistance to ALK inhibitors may occur due mutations in kinase domain.
	***Ceritinib is indicated for tumor with acquired resistance to crizotinib.<ref>{{Cite journal \| last1 = Shaw \| first1 = AT. \| last2 = Kim \| first2 = DW. \| last3 = Mehra \| first3 = R. \| last4 = Tan \| first4 = DS. \| last5 = Felip \| first5 = E. \| last6 = Chow \| first6 = LQ. \| last7 = Camidge \| first7 = DR. \| last8 = Vansteenkiste \| first8 = J. \| last9 = Sharma \| first9 = S. \| title = Ceritinib in ALK-rearranged non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 370 \| issue = 13 \| pages = 1189-97 \| month = Mar \| year = 2014 \| doi = 10.1056/NEJMoa1311107 \| PMID = 24670165 }}</ref>		***Ceritinib is indicated for tumor with acquired resistance to crizotinib.<ref>{{Cite journal \| last1 = Shaw \| first1 = AT. \| last2 = Kim \| first2 = DW. \| last3 = Mehra \| first3 = R. \| last4 = Tan \| first4 = DS. \| last5 = Felip \| first5 = E. \| last6 = Chow \| first6 = LQ. \| last7 = Camidge \| first7 = DR. \| last8 = Vansteenkiste \| first8 = J. \| last9 = Sharma \| first9 = S. \| title = Ceritinib in ALK-rearranged non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 370 \| issue = 13 \| pages = 1189-97 \| month = Mar \| year = 2014 \| doi = 10.1056/NEJMoa1311107 \| PMID = 24670165 }}</ref>
	*Testing in FFPE requires ~100 cells.<ref name=pmid25806315>{{Cite journal \| last1 = Popper \| first1 = HH. \| last2 = Tímár \| first2 = J. \| last3 = Ryska \| first3 = A. \| last4 = Olszewski \| first4 = W. \| title = Minimal requirements for the molecular testing of lung cancer. \| journal = Transl Lung Cancer Res \| volume = 3 \| issue = 5 \| pages = 301-4 \| month = Oct \| year = 2014 \| doi = 10.3978/j.issn.2218-6751.2014.10.02 \| PMID = 25806315 }}</ref>		*Testing in [[FFPE]] requires ~100 cells.<ref name=pmid25806315>{{Cite journal \| last1 = Popper \| first1 = HH. \| last2 = Tímár \| first2 = J. \| last3 = Ryska \| first3 = A. \| last4 = Olszewski \| first4 = W. \| title = Minimal requirements for the molecular testing of lung cancer. \| journal = Transl Lung Cancer Res \| volume = 3 \| issue = 5 \| pages = 301-4 \| month = Oct \| year = 2014 \| doi = 10.3978/j.issn.2218-6751.2014.10.02 \| PMID = 25806315 }}</ref>

	==Microscopic==		==Microscopic==

Michael at 13:17, 19 October 2017

2017-10-19T13:17:54Z

← Older revision		Revision as of 13:17, 19 October 2017
Line 8:		Line 8:
	***Resistance to ALK inhibitors may occur due mutations in kinase domain.		***Resistance to ALK inhibitors may occur due mutations in kinase domain.
	***Ceritinib is indicated for tumor with acquired resistance to crizotinib.<ref>{{Cite journal \| last1 = Shaw \| first1 = AT. \| last2 = Kim \| first2 = DW. \| last3 = Mehra \| first3 = R. \| last4 = Tan \| first4 = DS. \| last5 = Felip \| first5 = E. \| last6 = Chow \| first6 = LQ. \| last7 = Camidge \| first7 = DR. \| last8 = Vansteenkiste \| first8 = J. \| last9 = Sharma \| first9 = S. \| title = Ceritinib in ALK-rearranged non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 370 \| issue = 13 \| pages = 1189-97 \| month = Mar \| year = 2014 \| doi = 10.1056/NEJMoa1311107 \| PMID = 24670165 }}</ref>		***Ceritinib is indicated for tumor with acquired resistance to crizotinib.<ref>{{Cite journal \| last1 = Shaw \| first1 = AT. \| last2 = Kim \| first2 = DW. \| last3 = Mehra \| first3 = R. \| last4 = Tan \| first4 = DS. \| last5 = Felip \| first5 = E. \| last6 = Chow \| first6 = LQ. \| last7 = Camidge \| first7 = DR. \| last8 = Vansteenkiste \| first8 = J. \| last9 = Sharma \| first9 = S. \| title = Ceritinib in ALK-rearranged non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 370 \| issue = 13 \| pages = 1189-97 \| month = Mar \| year = 2014 \| doi = 10.1056/NEJMoa1311107 \| PMID = 24670165 }}</ref>
			*Testing in FFPE requires ~100 cells.<ref name=pmid25806315>{{Cite journal \| last1 = Popper \| first1 = HH. \| last2 = Tímár \| first2 = J. \| last3 = Ryska \| first3 = A. \| last4 = Olszewski \| first4 = W. \| title = Minimal requirements for the molecular testing of lung cancer. \| journal = Transl Lung Cancer Res \| volume = 3 \| issue = 5 \| pages = 301-4 \| month = Oct \| year = 2014 \| doi = 10.3978/j.issn.2218-6751.2014.10.02 \| PMID = 25806315 }}</ref>

	==Microscopic==		==Microscopic==

← Older revision		Revision as of 18:31, 8 March 2019
Line 61:		Line 61:
	*[[Lung tumours]].		*[[Lung tumours]].
	*[[Lung carcinoma with EGFR mutation]].		*[[Lung carcinoma with EGFR mutation]].
			*[[ALK translocation renal cell carcinoma]].

	==References==		==References==